Skip to main content
. 2017 Aug 28;4(2):233–246. doi: 10.1007/s40744-017-0076-0

Table 1.

Secondary endpoints of FUTURE-1 and FUTURE-2 trials

Secondary endpoints Measure
Psoriasis Area Severity Index (PASI) 75 Improvement in psoriasis symptoms
Health Assessment Questionnaire Disability Index (HAQ-DI) Quality of life
SF-36 Physical Component Summary (PCS) score Quality of life
Disease Activity Score (DAS)28-CRP Disease activity